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Abstract 29 
Background. Cell-free fetal DNA (cffDNA) non-invasive prenatal testing (NIPT) is 30 
rapidly expanding and being introduced at varying rates depending on country and 31 
condition. 32 
Objectives. Determine accuracy of cffDNA-based NIPT for all conditions. Evaluate 33 
influence of other factors on test performance.  34 
Search strategy. Medline, Embase, CINAHL, Cochrane Library, 1997-April 2015.  35 
Selection criteria. Cohort studies reporting cffDNA-based NIPT performance in 36 
singleton pregnancies.  37 
Data collection and analysis. Bivariate or univariate meta-analysis and sub-group 38 
analysis performed to explore influence of test type and population risk. . 39 
Main results. 117 studies included which analysed 18 conditions. Bivariate meta-40 
analysis demonstrated sensitivities and specificities respectively for: fetal sex 41 
0.989(95%CI 0.980-0.994) and 0.996(95%CI 0.989-0.998) 11,179 tests; Rhesus D 42 
0.993(0.982-0.997) and 0.984(0.964-0.993) 10,290 tests; trisomy 21 0.994(0.983-43 
0.998) and 0.999(0.999-1.00) 148,344 tests; trisomy 18 0.977(0.952-0.989) and 44 
0.999(0.998-1.00) 146,940 tests; monosomy X 0.929(0.741-0.984) and 0.999(0.995-45 
0.999) 6,712 tests. Trisomy 13 was analysed by univariate meta-analysis with a 46 
summary sensitivity of 0.906(95%CI 0.823-0.958) and specificity of 1.00(95%CI 0.999-47 
0.100) 134,691 tests. False and inconclusive results were poorly reported across all 48 
conditions. Test type did affect sensitivity and specificity, but there was no evidence 49 
that population risk did. 50 
Conclusions. Performance of cffDNA-based NIPT is affected by condition under 51 
investigation. For fetal sex and Rhesus status NIPT can be considered diagnostic. For 52 
trisomy 21, 18 and 13, the lower sensitivity, specificity and disease prevalence 53 
combined with the biological influence of confined placental mosaicism designates it a 54 
screening test. These factors must be considered when counselling patients and 55 
assessing the cost of introduction into routine care. 56 
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Systematic review registration. PROSPERO CRD42014007174 57 
 58 
Keywords. cell-free fetal DNA, non-invasive prenatal testing, diagnostic accuracy 59 
Tweetable abstract. cffDNA NIPT accuracy high, can be diagnostic for fetal sex and 60 
Rhesus, but only screening test in aneuploidy 61 
 62 
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Introduction 63 
Non-invasive prenatal testing (NIPT) utilises cell-free fetal DNA (cffDNA) present in 64 
maternal plasma and believed to originate from trophoblast. It was first detected by Lo 65 
et al. in 1997 (1) and used to note the presence of the Y chromosome to diagnose fetal 66 
sex. NIPT can now be used to test for aneuploidy, and single gene disorders such as 67 
cystic fibrosis, Huntington’s disease or thanatophoric dysplasia (2-6). Its advantage is 68 
that it is non-invasive, avoiding the 0.5-1% risk of miscarriage associated with 69 
amniocentesis/chorionic villus sampling (7) and allows timely therapeutic intervention in 70 
conditions such as congenital adrenal hyperplasia (CAH) (8). cffDNA is cleared from 71 
plasma (in hours) following delivery ensuring individuality for each pregnancy (9). Non-72 
invasive prenatal testing also has health economic implications eliminating the need to 73 
give all Rhesus negative women anti-D immunoglobulin prophylaxis.  74 
NIPT is being introduced into routine antenatal care across the world at differing 75 
speeds, largely influenced by technological advances facilitated by the commercial 76 
sector. Current guidance in North America and from the International Society for 77 
Prenatal Diagnosis advises a positive NIPT for aneuploidy to be confirmed by invasive 78 
testing (10-12) due to the low risk of a false positive result secondary to confined 79 
placental mosaicism (CPM). Inconclusive results occur in up to 8.1% (10), with a repeat 80 
sample being successful in up to 80% participants (13).  81 
Several systematic reviews and meta-analyses evaluating test accuracy have been 82 
published (14-18). However these have several limitations: i) they evaluate individual 83 
conditions (e.g. fetal sex, Rhesus status or aneuploidy) thus not allowing comparison; 84 
ii) have a high risk of bias as they include case-control studies; iii) utilise inferior 85 
statistical techniques for meta-analysis and iv) include studies with a significant risk of 86 
verification bias due to all participants not receiving a reference test (e.g. karyotype). 87 
The aim of our paper is to produce the most comprehensive systematic review and 88 
meta-analysis of NIPT and address these issues: include only cohort studies to reduce 89 
bias (19); perform bivariate meta-analysis where possible and thirdly to encompass all 90 
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indications for antenatal use, so as to enable a more uniformed comparison for the use 91 
of NIPT in clinical practice. We also aim to assess aspects of test accuracy that might 92 
influence how cffDNA is implemented in the clinical pathway e.g. effect of technique on 93 
accuracy and evaluation of false positive, false negative and inconclusive results. 94 
 95 
Methods 96 
This review was performed according to recommended methods (20-23) and an a priori 97 
designed and registered protocol (PROSPERO CRD42014007174).  98 
Identification of studies 99 
Medline, Web of Science, Embase, CINAHL and the Cochrane Library databases were 100 
searched for relevant articles by FLM. Grey literature and reference lists were hand 101 
searched. The search terms used were ‘noninvasive’, ‘non-invasive’, ‘non invasive’, 102 
‘prenatal diagnosis’, ‘cell free fetal DNA’ and ‘cell-free fetal DNA’. The full search 103 
strategy is available as online supplementary material (Appendix S1). The date of 104 
publication was limited from 1997 to 13 April 2015. There was no limitation on 105 
language.  106 
Study selection 107 
Study selection was performed in duplicate (FLM, RKM) involving screening of titles 108 
and abstracts, then reviewing full manuscripts of selected articles. Disagreements in 109 
selection were resolved by MDK. Articles were included based on the following criteria: 110 
Population: Women with a singleton pregnancy, any gestation. Populations could 111 
include women of varying risk with high-risk women defined as attending for testing due 112 
to pre-existing risk factors: a personal or family history of the condition being tested for, 113 
high-risk on routine biochemical screening, abnormal ultrasound scan, and/or raised 114 
maternal age. Women were considered low-risk if they had none of the above risk 115 
factors.  116 
Test: NIPT based on cffDNA in maternal blood, irrespective of condition being 117 
examined.  118 
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Reference standard: Studies must have compared all the cffDNA results with either: 119 
karyotype results or birth outcome (either blood sample or phenotype) as appropriate in 120 
all participants.  121 
Study design: Cohort studies.  122 
Exclusion criteria: pre-implantation testing, fetal cell testing, case-control studies, case 123 
series with <5 participants. 124 
Data extraction 125 
Data were extracted in duplicate on the relevant 2x2 tables comparing the non-invasive 126 
test with the reference test used for definitive diagnosis. Data were also extracted on 127 
factors which may affect test accuracy: participant characteristics (e.g. obstetric 128 
history); and test characteristics (e.g. cut offs used, test technique [e.g. PCR, MPS, 129 
mass spectrometry]). Information regarding false results and inconclusive results was 130 
obtained.  131 
When a study used similar laboratory protocols on the same blood samples (e.g. 132 
different number of replicates performed) only the best results were included. When a 133 
study used different laboratory protocols on different blood samples, but the same type 134 
of test technique, these samples were grouped together for analysis. If a study sub-135 
divided samples based on population characteristics (e.g. high-risk vs. low-risk for a 136 
condition, or 1st trimester vs. 2nd trimester vs. 3rd trimester) these were grouped 137 
together for the summary statistics, and analysed as a sub-group where appropriate.  138 
Quality Assessment 139 
The quality of the studies was assessed using the QUADAS-2 tool (24).  140 
Data synthesis 141 
For each study the 2x2 data were used to calculate sensitivity and specificity with 95% 142 
confidence intervals. Heterogeneity was explored by assessing the distribution of 143 
results in the Forest plots and summary receiver operating characteristic curves 144 
(SROC). Summary measures including sensitivities, specificities, diagnostic odds ratio, 145 
positive and negative likelihood ratios along with 95% confidence intervals were 146 
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calculated using bivariate logistic regression model with an unstructured correlation. 147 
This model allows for the correlation between sensitivity and specificity from the same 148 
study and for the sensitivities and specificities to have different random effects (25). 149 
Meta-analysis was performed when there were more than 5 studies per condition using 150 
STATA 13 (StataCorp. 2012, College Station, Texas) (see Appendix S2 for more 151 
detail). Sub-group analysis and meta-regression was planned a priori to assess effects 152 
of study level covariates on test accuracy, namely: population characteristics (level of 153 
risk for condition where appropriate i.e. not performed in fetal sex or Rhesus D); test 154 
technique (e.g. PCR, MPS) and quality aspects according to QUADAS-2. We used 155 
sub-group analyses (as opposed to meta-regression) to assess the influence of all 156 
categorical covariates due to model convergence difficulties (26).  157 
 158 
Results 159 
The search revealed 4433 studies for inclusion. After reviewing the full article, 117 160 
studies (1, 27-143) were eligible reporting on 18 different conditions, and 472,935 tests 161 
(Figure S1). The study characteristics are outlined in Table S1. 162 
We were able to produce summary results using the fully unstructured bivariate model 163 
for: fetal sex, Rhesus D, trisomy 21, trisomy 18 and monosomy X (Table S2). For 164 
trisomy 13, despite a sufficient number of studies (n=15) there was no heterogeneity in 165 
specificities across studies so the bivariate model, which takes into account the 166 
correlation between the sensitivities and specificities, failed to converge and 167 
consequently we fitted a univariate model. Because of this, these results are less 168 
methodologically robust. The HSROC curves are presented in Figure S2 and the 169 
results from our sub-group analyses in Table S2. 170 
There were 5 studies (n=394,130 tests) in which there was differential verification of 171 
results, in that some participants had their result confirmed by karyotype and others by 172 
phenotype (35, 91, 93, 114, 133). These 5 studies all assessed fetal aneuploidy and 173 
utilised NIPT as a screening test in a low-risk population. A sensitivity analysis 174 
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removing these 5 studies demonstrated no significant effect on the summary results, 175 
thus these studies are included in all analyses and Forest plots. 176 
The following 12 conditions had insufficient studies for meta-analysis: Rhesus C, 177 
Rhesus E, 47XXX, 47XXY, 47XYY, trisomy 16, congenital adrenal hyperplasia, 178 
deletion-duplication syndromes, sickle cell anaemia, thalassaemia, human platelet 179 
antigen 1a, and KEL 1. The Forest plots of these 12 conditions are presented in Figure 180 
S3. 181 
 182 
Methodological quality of included studies 183 
This was assessed according to the Quality Assessment tool for Diagnostic Accuracy 184 
Studies (QUADAS-2) (24), the results are demonstrated in Figure S4 and further 185 
described in Appendix S3.  186 
 187 
False results and inconclusive results 188 
Reporting of causes and implications of false positive, false negative and inconclusive 189 
results was poor, and varied across all conditions (Table S3). The included studies 190 
reported an inconclusive result rate of 0.32-5.3%. This issue was further compounded 191 
by a myriad of varying quality control (QC) standards, some studies excluding samples 192 
that failed their QC and others implementing no QC steps and therefore reporting some 193 
results as false negatives which other studies would have excluded from analysis. 194 
Some studies investigated the reasons for their false and inconclusive results and 195 
reported these clearly, accounting for all samples. Other studies reported inconclusive 196 
results as false negatives or did not report them at all. We describe these results in 197 
more detail for each of the conditions investigated. 198 
 199 
Results from bivariate meta-analysis 200 
 201 
Fetal Sex 202 
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Sixty studies (11,179 tests) evaluated fetal sex and are represented in the Forest plot 203 
in Figure 1. Bivariate meta-analysis produced a summary sensitivity of 0.989 (95% CI 204 
0.980 to 0.994) and specificity of 0.996 (95% CI 0.989 to 0.998), a positive likelihood 205 
ratio of 255 (95% CI 89 to 729) and negative likelihood ratio of 0.011 (95% CI 0.006 to 206 
0.019). Other summary measures are in Table S2. 207 
No significant effect on sensitivity was found with test technique. However there was a 208 
difference in specificity with real-time quantitative PCR 0.999 (95%CI 0.991 to 1.00) 209 
performing better than conventional PCR 0.939 (95%CI 0.872 to 0.972). For fetal sex, 210 
11/60 studies reported inconclusive results, of these, 5 studies documented an 211 
explanation (in order of frequency): assay failure, no reason given, insufficient number 212 
of markers present from pre-specified cut-off and low fetal fraction. The commonest 213 
reasons given by the authors of the studies for the false results were: no reason given, 214 
low fetal fraction (although cffDNA not quantified), low fetal fraction confirmed by 215 
authors quantifying cffDNA, possible contamination/DNA degradation/vanishing 216 
twin/test failure although not confirmed, and previous male pregnancy, although the 217 
latter reason has since been disproven as cell-free fetal DNA is cleared from the 218 
maternal circulation hours post-delivery (9).  219 
 220 
Rhesus D 221 
Thirty studies (10,290 tests) evaluated fetal Rhesus D status and are represented in 222 
Figure 2. Bivariate meta-analysis produced a summary sensitivity of 0.993 (95% CI 223 
0.982 to 0.997) and specificity of 0.984 (95% CI 0.964 to 0.993) a positive likelihood 224 
ratio of 61 (95% CI 22 to 167) and negative likelihood ratio of 0.007 (95% CI 0.003 to 225 
0.186). There was a significant difference between test techniques with real-time 226 
quantitative PCR sensitivity: 0.997 (95% CI 0.987 to 0.999) demonstrating a higher 227 
sensitivity than conventional PCR 0.924 (95%CI 0.832 to 0.968), although it was not 228 
possible to assess if there was a difference in those which utilised mass spectrometry 229 
(despite sufficient studies, due to convergence issues as detailed in the discussion), 230 
10 
 
and no difference in specificity was seen (Table S2). For Rhesus D, 13/30 studies 231 
reported inconclusive results, of these, 10 studies documented an explanation (in order 232 
of frequency): no reason given, RHD gene variant, insufficient number of markers 233 
present from pre-specified cut-off, test failure, low fetal fraction. The commonest 234 
reasons given for false results were: presumed low fetal fraction (although not 235 
quantified by authors), no reason given, presumed RHD gene variant (although not 236 
confirmed), confirmed RHD gene variant, test failure, possible contamination/DNA 237 
degradation/pipetting error/incorrect neonatal blood testing.  238 
 239 
Trisomy 21 240 
Thirty-one studies (148,344 tests) assessed trisomy 21 and are represented in Figure 241 
3A. Bivariate meta-analysis produced a summary sensitivity of 0.994 (95% CI 0.983 to 242 
0.998) and specificity of 0.999 (95% CI 0.999 to 1.00) a positive likelihood ratio of 1720 243 
(95% CI 1111 to 2662) and negative likelihood ratio of 0.006 (95% CI 0.002 to 0.017). 244 
Test technique and population risk had no significant effect. For trisomy 21, 14/31 245 
studies reported inconclusive results, of these, 7 studies documented an explanation 246 
(in order of frequency): assay failure, confirmed low fetal fraction, no reason given, 247 
presumed low fetal fraction/inadequate sequencing depth. The commonest reasons 248 
given for false results were: confirmed low fetal fraction, confirmed mosaicism, no 249 
reason given, test failure, maternal CNV.  250 
 251 
Trisomy 18 252 
Twenty-four studies (146,940 tests) assessed trisomy 18 and are represented in Figure 253 
3B. Bivariate meta-analysis produced a summary sensitivity of 0.977 (95% CI 0.952 to 254 
0.989) and specificity of 0.999 (95% CI 0.998 to 1.00) and a positive likelihood ratio of 255 
1569 (95% CI 810 to 3149) and negative likelihood ratio of 0.023 (95% CI 0.011 to 256 
0.048). Neither test technique or population risk had a significant effect. For trisomy 18, 257 
12/24 studies reported inconclusive results, of these 7 studies documented an 258 
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explanation (in order of frequency): low fetal fraction, test failure, no reason given, 259 
mosaicism. The commonest reasons given for false results were: confirmed low fetal 260 
fraction, confirmed mosaicism, presumed low fetal fraction/human error, maternal CNV, 261 
no reason given.  262 
 263 
Monosomy X 264 
Eight studies (6712 tests) assessed monosomy X and are represented in Figure 3C. 265 
Bivariate meta-analysis produced a summary sensitivity of 0.929 (95% CI 0.741 to 266 
0.984) and specificity of 0.999 (95% CI 0.995 to 0.999) and a positive likelihood ratio of 267 
1337 (95% CI 213 to 8407) and negative likelihood ratio of 0.071 (95% CI 0.017 to 268 
0.292). There was no significant difference with test technique. It was not possible to 269 
assess the effect of population risk as there were insufficient low-risk studies. For 270 
monosomy X, 5/8 studies reported inconclusive results, of these, 3 studies documented 271 
an explanation (in order of frequency): low fetal fraction, presumed human error and no 272 
reason given. The commonest reasons given for false results were: mosaicism and no 273 
reason given. 274 
 275 
The 5 aneuploidy studies which evaluated an unselected obstetric population reported 276 
inconclusive results rates of 0.29-5.1% and provided the same reasons for their false 277 
and inconclusive results as with the high-risk aneuploidy populations.  278 
 279 
Trisomy 13 – univariate meta-analysis 280 
Sixteen studies which equates to 134,691 tests examined trisomy 13, represented in 281 
Figure 3D. There was a summary sensitivity of 0.906 (95% CI 0.823 to 0.958) and 282 
specificity of 1.00 (95% CI 0.999 to 1.00). The positive likelihood ratio was 453 (95% CI 283 
26 to 7864) and negative likelihood ratio was 0.188 (95% CI 0.080 to 0.44039) with a 284 
diagnostic odds ratio of 2788 (95% CI 285 to 27252). For trisomy 13, 6/16 studies 285 
reported inconclusive results, of these, 4 studies documented an explanation for 286 
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inconclusive results: low fetal fraction, different fragmentation rate, contamination, 287 
assay failure and human error. The only reason given for false results was confirmed 288 
low fetal fraction.  289 
 290 
Results where meta-analysis not possible 291 
The results for these conditions are presented as Forest plots in S3.  292 
 293 
Clinical application for NIPT for Down’s syndrome screening 294 
Using published data from the National Down Syndrome Cytogenetic Register 295 
(NDSCR) 2012 Annual report we have produced a table detailing the estimated 296 
outcomes (livebirth rate, invasive test rate, euploid pregnancy loss rate, undiagnosed 297 
aneuploidy livebirth rate)  from the current standard Down’s Syndrome Screening 298 
(DSS) i.e. first trimester combined screening pathway (maternal age, nuchal 299 
translucency, beta human chorionic gonadotrophin and pregnancy associated plasma 300 
protein A) and from a pathway with NIPT as both contingent (i.e. NIPT offered to 301 
women with a positive screen after first trimester combined screening) and first line 302 
screening for a population of 100,000 women using crude rates (144) (Table S4). We 303 
use the prevalence reported by NDSCR1 (trisomy 21: 2.2 per 1000 women, trisomy 18: 304 
0.64 per 1000, trisomy 13 0.26 per 1000). This assumes that standards for the first 305 
trimester combined screening are “achievable” as described by Fetal Anomaly 306 
Screening Programme (FASP) guidance i.e. for trisomy 21 a detection rate of 85% for 307 
a screen positive rate of 2% (145). For NIPT the summary measures are those from 308 
our meta-analysis. For the contingent screening model the cut-off for high risk is 1:1000 309 
from first trimester combined screening with a detection rate of 96% and false positive 310 
rate of 12% (146). This model assumes that all women accept screening when offered 311 
as it is not possible to determine yet what the uptake of NIPT would be if offered as a 312 
first-line test. It also assumes that all women are required to have an invasive test for 313 
karyotyping after a screen positive result from combined or NIPT prior to considering 314 
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termination of pregnancy, thus the invasive test rates will be higher than in a real-life 315 
population. It assumes a 0.5% pregnancy loss rate from invasive testing (146). 316 
 317 
These data demonstrate the influence of disease prevalence on test performance. If we 318 
compare combined screening with a 1:150 cut-off (i.e. current NHS practice) with NIPT 319 
as a first–line test we can reduce the invasive test rate from 2000 to 319 per 100,000 320 
women, the euploid pregnancy loss rate from 9 to 1 per 100,000 and the undiagnosed 321 
trisomy 21 live births rate from 32 to 1 per 100,000. If NIPT was used as a contingent 322 
screening test for a 1:1000 combined screening cut-off (i.e. as a 2nd test following a 323 
positive combined screening result at a 1:1000 cut-off) then these figures are reduced 324 
even further compared to combined screening with a 1:150 cut-off: 2000 to 222 per 325 
100,000 women invasive test rate; 9 to 0 euploid pregnancy loss rate, although there is 326 
less of a reduction in undiagnosed trisomy 21 live birth rate from 32 to 10. If NIPT was 327 
used as a contingent screening test for a 1:150 combined screening cut-off then these 328 
figures are: 2000 per 100,000 women invasive test rate; 0 euploid pregnancy loss and 329 
34 undiagnosed trisomy 21 livebirth rate. A two stage contingent screening pathway 330 
with a 1:1000 cut-off when compared to NIPT as a first line test affords a reduction in 331 
false positive results (12 versus 100 per 100,000 women) that are found at the time of 332 
NIPT as the prevalence of disease in the population now undergoing NIPT is much 333 
higher. This is at the expense of a 10 fold increase in undiagnosed aneuploidy live 334 
births (1 versus 10 per 100,000 women) due to the increased number of false 335 
negatives at the first stage of screening that do not undergo NIPT. A cut-off of 1:150 at 336 
the first stage for the combined test compared to a 1:150 cut-off for NIPT as a 337 
contingent screening test has little effect on the number false negatives (33 versus 34), 338 
however the invasive test rate is reduced (2000 versus 188 per 100,000 women). 339 
 340 
Discussion 341 
Main findings 342 
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Our results demonstrate that for fetal sex and Rhesus D status, cffDNA-based NIPT 343 
has a high sensitivity and specificity. For aneuploidies: trisomy 21, and in particular 344 
trisomy 18 and 13 we have demonstrated improved accuracy from other recent 345 
systematic reviews likely due to technological developments. Importantly we found that 346 
false results and inconclusive results were poorly reported across all conditions.  347 
 348 
Strengths and limitations 349 
This review was performed according to rigorous methodology with efforts made to 350 
reduce bias in participant selection and clinical applicability by excluding case-control 351 
studies, performing bivariate meta-analysis and meta-regression analysis and 352 
assessing the impact of differential verification (i.e. different reference standards). 353 
Bivariate meta-analysis is the recommended approach for the meta- analysis of 354 
diagnostic test accuracy studies. This is because a conventional univariate analysis 355 
makes assumptions that are known not to be tenable (that the sensitivity and specificity 356 
from the same study are independent). However, the bivariate meta-analysis model is 357 
a technically difficult model to fit and it is well known that these models might not 358 
converge when there are a small number of studies, or when there are zero cells (i.e. 359 
sensitivity or specificity close to 100) (26). We observed no indication that other model 360 
fits were unstable and so have no reason to be concerned about the statistical validity 361 
of the other results.  Our review also evaluates more conditions than previously. In 362 
addition, our paper has been able to assess the impact of test technique and 363 
population risk. We were unable to evaluate the number of samples which failed QC 364 
measures as this was reported in varying degrees. When considering the 365 
implementation of a new test, information regarding failed tests (147, 148), and 366 
inconclusive results is vital. We investigated the reasons for false positive and false 367 
negative results within and across studies and attempted to summarise these. This was 368 
again hampered by poor reporting with a common reason being low fetal fraction which 369 
is difficult to measure accurately and thus has led to variations in approach between 370 
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studies. It is especially important to consider this further as low fetal fraction has been 371 
shown to be associated with trisomy 18 and triploidies. 372 
A limitation of this work is that it was not possible to account for the many subtle 373 
differences in laboratory techniques such as comparing the different combinations of 374 
genetic markers used for each condition; or the myriad of adjustments made to 375 
bioinformatics algorithms as these were so varied. This is where the results from the 376 
large studies in screening populations are especially important as there is QC across 377 
laboratories and standardisation of techniques (35, 91, 93, 114, 133). In the process of 378 
publishing this review, the search was re-run from April 2015 - September 2015 in view 379 
of the rapid progression in this area. This yielded 78 new citations, of which 11 380 
additional papers would be eligible for inclusion (3, 149-158), which comprise 10,191 381 
women in total. These studies examine fetal sex (n=436 women), Rhesus D status 382 
(n=2965), trisomy 21 (n=6661), trisomy 18 (n=6701), trisomy 13 (n=6495), and 383 
monosomy X (n=40), which equate to a small proportion of additional tests, compared 384 
to the studies we have already analysed. There is also now one study which 385 
investigates thanatophoric dysplasia (n=108), although this cannot be included in a 386 
meta-analysis as it is the only study to look at this condition thus far. As the search was 387 
under a year old when the publication was accepted we have not included these 11 388 
studies in our results. We are confident that if these studies were included they would 389 
not impact on our results and conclusions. 390 
 391 
Interpretation 392 
It is recognised that there are fewer studies in our meta-analyses for trisomy 13 and 393 
monosomy X compared to a previous large meta-analysis (14) but this is due to 394 
excluding case-control studies and limiting to singletons. This has led to us reporting 395 
higher summary sensitivities and specificities than existing analyses, demonstrating 396 
how NIPT is advancing, and supporting the belief that NIPT will be used as the first-line 397 
screening test in the future. Our clinical application model has highlighted the 398 
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importance of low prevalence of disease on the positive predictive value and false 399 
positive rate in the case of aneuploidies. Although positive and negative predictive 400 
values are useful indicators of test accuracy as they take into account disease 401 
prevalence (159), we have not presented these values within this paper due to 402 
variation in disease prevalence among included study populations. 403 
 404 
Conclusion 405 
This work demonstrates that there is a sufficient body of evidence for the accuracy and 406 
reproducibility of cffDNA-based NIPT to allow its introduction into routine clinical 407 
practice within the UK, however its role is yet to be decided. 408 
 409 
Implications for clinical practice 410 
The findings of this analysis support the use of NIPT as a diagnostic test for fetal sex 411 
and Rhesus status due to the nature of these conditions and the populations being 412 
tested. For assessment of aneuploidy the test must be considered a “screening test” 413 
despite high accuracy due to the low prevalence of disease and influence of biological 414 
factors such as CPM. We are aware that the National Screening Committee (NSC) is 415 
currently reviewing all the evidence for aneuploidy, and is likely to recommend NIPT as 416 
a contingency screening test in the UK (Dr Pranav Pandya, Personal Communication, 417 
2015). While for Down’s syndrome screening (DSS) this will ensure access to an 418 
accurate, non-invasive test and ensure equity for many more women (i.e. test threshold 419 
has less of an impact on offering invasive testing and test can be offered throughout 420 
gestation not just in a small first trimester window) this must be balanced with 421 
consideration of the important ethical repercussions which need addressing (i.e. a test 422 
that can assess for multiple conditions and those with a milder phenotype and also test 423 
for conditions within the mother e.g. sex-chromosome anomaly or cancers) (160). 424 
There are also counselling implications as access to a non-invasive, highly accurate 425 
test still needs careful consideration by parents.   426 
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 427 
Implications for future research 428 
The authors would recommend that the same rigorous assessment of the evidence and 429 
accuracy as we have performed be applied in multiple pregnancies once the evidence 430 
base is sufficient. 431 
The NIHR funded RAPID study which has used NIPT in an NHS setting for women in 432 
whom combined testing gave a risk of ≥ 1:1000 will soon be published. This study aims 433 
to assess the uptake of NIPT and whether the addition of NIPT to the DSS pathway 434 
affects the uptake of DSS and invasive testing; a detailed health economic evaluation 435 
using a tool developed in conjunction with the UK NSC; optimal ways to deliver 436 
education to women and healthcare professionals; and sensitivity and specificity of 437 
NIPT for aneuploidy when performed in an NHS regional genetics laboratory. The 438 
results from our review indicate the latter (accuracy results from an NHS regional 439 
genetics laboratory) will be an important outcome as it will remove the influence of 440 
results from the commercial sector and poor reporting. This will allow for improved QC, 441 
enable continued assessment on a national basis, and ensure that the cost of NIPT will 442 
improve further. Similarly, the conditions for which NIPT will be used are likely to 443 
increase; 11 studies which examined single gene mutations and microdeletions could 444 
not be included in our meta-analysis due to having fewer than 5 participants; even 445 
whilst writing this review larger studies are being reported on these conditions (161). 446 
However, an economic evaluation of this first-line screening with NIPT would also need 447 
to include maintaining access to a high quality first trimester ultrasound scan including 448 
nuchal translucency (NT) assessment, to allow dating, viability, multiple pregnancy, 449 
structural anomaly and adnexal assessment, and importantly the assessment of the 450 
risk of cardiac anomalies and increased pregnancy loss associated with raised NT. 451 
 452 
 453 
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Figure 1: Forest plot of studies testing fetal sex using cell-free fetal DNA 
 
 
Figure 2: Forest plot of studies testing Rhesus D status using cell-free fetal DNA 
 
 
 
 
 
 
Figure 3A: Forest plot of studies testing Trisomy 21 using cell-free fetal DNA 
 
Figure 3B: Forest plot of studies testing Trisomy 18 using cell-free fetal DNA 
 
 
Figure 3C: Forest plot of studies testing Monosomy X using cell-free fetal DNA 
 
Figure 3D: Forest plot of studies testing Trisomy 13 using cell-free fetal DNA 
 
 
  
